Overview During Brazil’s intense dengue surge in 2024, a tetravalent vaccine known as Qdenga was used in a real-world setting to protect adolescents. Researchers reported that vaccination reduced hospitalizations by up to 68% among those who contracted dengue, marking the first real-world evidence of Qdenga’s effectiveness after its authorization. The campaign unfolded against a backdrop…